ESC/EAS Guidelines for the management of dyslipidaemias

Catapano, Alberico L.; Reiner, Željko; Backer, Guy De; Graham, Ian; Taskinen, Marja‐Riitta; Wiklund, Olov; Agewall, Stefan; Alegría, Eduardo; Chapman, M. John; Durrington, Paul N.; Erdine, Serap; Halcox, Julian; Hobbs, FD Richard; Kjekshus, John; Filardi, Pasquale Perrone; Riccardi, Gabriele; Storey, Robert F.; Wood, David

doi:10.1016/j.atherosclerosis.2011.06.012

Cited by 323 publications

(336 citation statements)

References 211 publications

Supporting

Mentioning

274

Contrasting

Unclassified

Order By: Relevance

“…We believe that global positive evaluation of HTE-DLPR is due to the significant participation of vascular risk experts in the design of its hardware and software [14]. Therefore, clinicians have ensured that HTE-DLPR is faithful to top scientific evidence and the recommendations of the European Society of Arteriosclerosis [15]. A recent survey showed that only in 67% of medical APPs expert involvement and in 87% of cases adherence to medical evidence was found [18].…”

Section: Discussionmentioning

confidence: 99%

“…HTE-DLPR performs a sequence of clinical decisions as expert lipidologyst including all statins and ezetimibe and creates specific recommendations for each patient using efficiency, safety and cost criteria. A multi-center observational prospective study has revealed that the number of patients at very high cardiovascular risk, reaching the treatment goal defined by the European Guidelines for the Management of Dyslipidemia 2011 [15] (LDL-C < 70 mg/dL. ), increases 4.4 times when expert clinicians in the lipidology field use HTE-DL-PR [14].…”

Section: International Journal Of Cardiovascular Practicementioning

confidence: 99%

“…European Guidelines for the Management of Dyslipidemia 2011 [15] and its scientific content has been verified by two experts' lipidologist using peer-review method. Equally, two independent computer engineers have tested the software and hardware and certified that HTE-DLPR met the rules on confidentiality and data protection of patients.…”

Section: International Journal Of Cardiovascular Practicementioning

confidence: 99%

See 2 more Smart Citations

Evaluation of a Clinical Decision Support System for Dyslipidemia Treatment (HTE-DLPR) by QoE questionnaire

Zamora¹,

Carrión²,

Aymerich³

et al. 2017

ijcp

View full text Add to dashboard Cite

Introduction: Clinical decision support systems (CDSS) are computer systems designed to assist clinicians with patient-related decision making, such as diagnosis and treatment. CDSS have shown to improve both patient outcomes and cost of care. Methods: A multi-center observational prospective study was conducted. Ten physicians agreed to participate. Seventy-seven patients with high or very high cardiovascular risk were included. After using CDSS for dyslipidemia (HTE-DLPR) for a 3 months period, participants were asked to evaluate their experience with HTE-DLPR using a quality of experience questionnaire (QoE) tool for mHealth applications. Results: Total score on the QoE was 3.89 out of 5. The highest scores were received for precision, ease of use and content quality. The lowest scores were given to security, appearance and performance. Physicians were in strong agreement with the 1st HTE-DLPR recommendation in 86.1% and the system's use was described as comfortable in 85% of cases. Users positively evaluated the development of a new version of HTE-DLPR in the future receiving a total score of 4.25 out of 5. Conclusions: A CDSS for dyslipidemia (HTE-DLP) has been positively evaluated by physicians using QoE questionnaire.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: International Journal Of Cardiovascular Practicementioning

confidence: 99%

Section: International Journal Of Cardiovascular Practicementioning

confidence: 99%

See 1 more Smart Citation

Evaluation of a Clinical Decision Support System for Dyslipidemia Treatment (HTE-DLPR) by QoE questionnaire

Zamora¹,

Carrión²,

Aymerich³

et al. 2017

ijcp

View full text Add to dashboard Cite

show abstract

“…Cardiovascular disease (CVD) due to atherosclerosis of the arterial vessel wall is the leading cause of premature mortality in Europe [5,6]. [7].…”

Section: Discussionmentioning

confidence: 99%

The Correlation between LDL-C and Non-HDL-C Levels and Cardiovascular Events in Patients with Metabolic Syndrome

Gierach¹,

Skowrońska²

2016

Endocrinol Metab Syndr

View full text Add to dashboard Cite

In 1988 Reaven described polymorphic metabolic abnormalities involving the incidence of insulin resistance with compensatory hyperinsulinemia, type 2 diabetes mellitus, arterial hypertension and hypercholesterolemia also known as Reaven's syndrome or syndrome X. The aim of the study was to evaluate if cardiovascular risk in patients with metabolic syndrome [MetS] correlate with LDL-C and non-HDL-C levels. The study was a prospective, twocenter screening study of 36-month duration located in University Hospital No.1 in Bydgoszcz, Poland and District Hospital in Wąbrzezno, Poland. The study included 906 participants (460 females [F], 446 males [M], aged 32-76 years), with a confirmed diagnosis of metabolic syndrome according to the 2005 IDF criteria. The study showed that LDL-C and non-HDL-C levels are connected with increased level of triglycerides and impaired fasting glucose. Levels of LDL-C and non-HDL-C also influenced hypertension and hypoalfalipoproteinemia to a lesser extent and exerted the least influence in individuals with type 2 diabetes mellitus. The study proved that the components of metabolic syndrome, especially abdominal obesity, hypertriglyceridemia, and impaired fasting glucose have a major impact on the level of LDL and non-HDL-C, which is associated with a higher cardiovascular risk.

show abstract

“…Las estatinas son la terapia farmacológica de elección en la mayoría de los pacientes para reducir el colesterol sérico y son recomendadas para prevención primaria y secundaria de la enfermedad coronaria por guías de práctica clínica de diversas sociedades científicas (21)(22)(23). Durante los últimos años han surgido nuevos tratamientos que buscan una reducción mayor del colesterol y en una mayor cantidad de pacientes.…”

Section: Asignación: Aleatoriaunclassified

Ronda clínica y epidemiológica: club de revistas

Galeano

Restrepo

Caraballo

et al. 2017

iatreia

View full text Add to dashboard Cite

RESUMENEn esta edición de la Ronda Clínica y Epidemiológica analizamos cuatro artículos que consideramos relevantes para la práctica clínica. Spaite y colaboradores estudian por primera vez en la literatura médica el verdadero significado pronóstico de un valor exacto que defina hipotensión arterial pre-hospitalaria, en el contexto de la reanimación del paciente con trauma craneoencefálico moderado a grave. Oluwalana y colaboradores estudian el impacto de la administración oral de azitromicina durante el periparto en el riesgo de infecciones maternas y neonatales. Por otro lado, Esplin y colaboradores estudian la capacidad de la cervicometría y la fibronectina fetal seriada, solas o en combinación, para predecir la probabilidad de parto pretérmino espontáneo en gestantes nulíparas. Finalmente, el estudio del grupo FOURIER evalúa el efecto de la reducción de los niveles de colesterol LDL lograda con la administración de evolocumab, en pacientes con evidencia clínica de enfermedad cardiovascular que reciben tratamiento optimizado con estatinas, en el riesgo del desenlace compuesto por muerte cardiovascular, accidente cerebrovascular isquémico, infarto de miocardio u hospitalización por angina inestable o revascularización coronaria.

show abstract

ESC/EAS Guidelines for the management of dyslipidaemias

Cited by 323 publications

References 211 publications

Evaluation of a Clinical Decision Support System for Dyslipidemia Treatment (HTE-DLPR) by QoE questionnaire

Evaluation of a Clinical Decision Support System for Dyslipidemia Treatment (HTE-DLPR) by QoE questionnaire

The Correlation between LDL-C and Non-HDL-C Levels and Cardiovascular Events in Patients with Metabolic Syndrome

Ronda clínica y epidemiológica: club de revistas

Contact Info

Product

Resources

About